ArticleChina CDC weekly2025
World Hepatitis Day 2025: Progress and Challenges in the Global Elimination of Viral Hepatitis.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Low seroprevalence of hepatitis B virus and absence of hepatitis C virus among patients attending dental clinics in Mogadishu, Somalia.BMC gastroenterology · 2026Article
- Seroprevalence and risk factors of HBV/HCV/HIV triple co-infection among HIV patients receiving HAART at a Tertiary Hospital in Makurdi, Nigeria.The Pan African medical journal · 2026Article
- HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The year 2025 marks the 15th anniversary of World Hepatitis Day, a milestone that has witnessed remarkable progress in global viral hepatitis prevention and treatment. This article systematically examines the establishment and evolution of World Hepatitis Day, emphasizing the latest achievements in hepatitis control through 2025. Current data demonstrate that global hepatitis B vaccine coverage has surpassed the 90% target, while a cumulative 12,748,000 hepatitis C patients received direct-acting antivirals (DAAs) treatment from 2014 to 2023. Despite these advances, persistent challenges, including suboptimal diagnosis rates and pronounced regional disparities continue to impede progress toward the 2030 elimination objectives. Drawing from the most recent epidemiological data, this article presents targeted recommendations to accelerate global elimination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.